Piper Sandler maintains argenx at Overweight, raises price target to $1350 from $1215
Piper Sandler raised its price target for argenx to $1350 from $1215, an 11.1% increase, implying 53.7% upside from the Nov 13 close. Recent analyst targets range from $1090 to $1336.
How this was made

The 30-second read
Why it matters
The price target increase signals confidence in upcoming milestones, but the actual catalyst remains pending.
Market read
Analyst target upgrades can drive short-term price moves, especially in high‑volatility biotech stocks.
What to watch
Potential dilution from upcoming financing rounds not addressed.
Background
argenx is a clinical-stage biotech developing antibody therapies. Analyst coverage influences its valuation.
Ticker impact
Piper Sandler raised its price target on argenx to $1350 from $1215, indicating a fresh bullish analyst view.
potential upside pressure as the market prices in the higher target
The new target suggests a 53.7% upside from the recent close, likely prompting short-term interest.
Market effects
May lift sentiment in the biotech sector as peers see similar analyst optimism.
Limited to US-listed biotech investors.
Low global impact beyond sector.
Counterpoint
The target raise could be premature if upcoming trial data disappoints.
Key entities
- AnalystPiper Sandler
Equity research firm that raised the price target.
- Companyargenx
Biotech firm receiving the upgraded target.


